These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24812279)

  • 1. P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.
    Zhu W; Zhang W; Shou W; Field LJ
    Cardiovasc Res; 2014 Jul; 103(1):81-9. PubMed ID: 24812279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted expression of cyclin D2 ameliorates late stage anthracycline cardiotoxicity.
    Zhu W; Reuter S; Field LJ
    Cardiovasc Res; 2019 Apr; 115(5):960-965. PubMed ID: 30423020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway.
    Zhu W; Soonpaa MH; Chen H; Shen W; Payne RM; Liechty EA; Caldwell RL; Shou W; Field LJ
    Circulation; 2009 Jan; 119(1):99-106. PubMed ID: 19103993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serine mutations in overexpressed Hsp27 abrogate the protection against doxorubicin-induced p53-dependent cardiac apoptosis in mice.
    Kanagasabai R; Karthikeyan K; Zweier JL; Ilangovan G
    Am J Physiol Heart Circ Physiol; 2021 Nov; 321(5):H963-H975. PubMed ID: 34477462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure.
    Singh KK; Shukla PC; Quan A; Desjardins JF; Lovren F; Pan Y; Garg V; Gosal S; Garg A; Szmitko PE; Schneider MD; Parker TG; Stanford WL; Leong-Poi H; Teoh H; Al-Omran M; Verma S
    J Biol Chem; 2012 Feb; 287(9):6604-14. PubMed ID: 22157755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes.
    Feridooni T; Hotchkiss A; Remley-Carr S; Saga Y; Pasumarthi KB
    PLoS One; 2011; 6(7):e22801. PubMed ID: 21829519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
    Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
    Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53.
    Zhang C; Feng Y; Qu S; Wei X; Zhu H; Luo Q; Liu M; Chen G; Xiao X
    Cardiovasc Res; 2011 Jun; 90(3):538-45. PubMed ID: 21278141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress.
    Zhao D; Xue C; Li J; Feng K; Zeng P; Chen Y; Duan Y; Zhang S; Li X; Han J; Yang X
    Biochem Biophys Res Commun; 2020 Dec; 533(3):304-312. PubMed ID: 32958254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cyclin-dependent kinase 7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy.
    Chen J; Wei J; Xia P; Liu Y; Belew MD; Toohill R; Wu BJ; Cheng Z
    Cardiovasc Res; 2024 Jul; 120(9):1024-1036. PubMed ID: 38646672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-146a attenuates apoptosis and modulates autophagy by targeting TAF9b/P53 pathway in doxorubicin-induced cardiotoxicity.
    Pan JA; Tang Y; Yu JY; Zhang H; Zhang JF; Wang CQ; Gu J
    Cell Death Dis; 2019 Sep; 10(9):668. PubMed ID: 31511497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HSP27 regulates p53 transcriptional activity in doxorubicin-treated fibroblasts and cardiac H9c2 cells: p21 upregulation and G2/M phase cell cycle arrest.
    Venkatakrishnan CD; Dunsmore K; Wong H; Roy S; Sen CK; Wani A; Zweier JL; Ilangovan G
    Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1736-44. PubMed ID: 18263706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy.
    Xia P; Liu Y; Chen J; Coates S; Liu DX; Cheng Z
    J Biol Chem; 2018 Dec; 293(51):19672-19685. PubMed ID: 30361442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways.
    Ma J; Wang Y; Zheng D; Wei M; Xu H; Peng T
    Cardiovasc Res; 2013 Jan; 97(1):77-87. PubMed ID: 23027656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsp70 regulates the doxorubicin-mediated heart failure in Hsp70-transgenic mice.
    Naka K K; Vezyraki P; Kalaitzakis A; Zerikiotis S; Michalis L; Angelidis C
    Cell Stress Chaperones; 2014 Nov; 19(6):853-64. PubMed ID: 24748476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Senescence marker protein 30 has a cardio-protective role in doxorubicin-induced cardiac dysfunction.
    Miyata M; Suzuki S; Misaka T; Shishido T; Saitoh S; Ishigami A; Kubota I; Takeishi Y
    PLoS One; 2013; 8(12):e79093. PubMed ID: 24391705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MG53 inhibits ferroptosis by targeting the p53/SLC7A11/GPX4 pathway to alleviate doxorubicin-induced cardiotoxicity.
    Jiang W; Yu L; Mu N; Zhang Z; Ma H
    Free Radic Biol Med; 2024 Oct; 223():224-236. PubMed ID: 39111582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity.
    Yoshida M; Shiojima I; Ikeda H; Komuro I
    J Mol Cell Cardiol; 2009 Nov; 47(5):698-705. PubMed ID: 19660469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21(Cip1.).
    Cheng Z; DiMichele LA; Rojas M; Vaziri C; Mack CP; Taylor JM
    J Mol Cell Cardiol; 2014 Feb; 67():1-11. PubMed ID: 24342076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice.
    Shizukuda Y; Matoba S; Mian OY; Nguyen T; Hwang PM
    Mol Cell Biochem; 2005 May; 273(1-2):25-32. PubMed ID: 16013437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.